Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial.

Benedetta Conte; Marco Bruzzone; Matteo Lambertini; Francesca Poggio; Claudia Bighin; Eva Blondeaux; Michelino De Laurentiis; Enrichetta Valle; Francesco Cognetti; Cecilia Nisticò; Sabino De Placido; Ornella Garrone; Teresa Gamucci; Filippo Montemurro; Fabio Puglisi; Barbara Cardinali; Piero Fregatti; Loredana Miglietta; Francesco Boccardo; Marcello Ceppi; Lucia Del Mastro; GIM2 Investigators

doi:10.1016/j.ejca.2020.05.007

Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial.

Benedetta Conte, Marco Bruzzone, Matteo Lambertini, Francesca Poggio, Claudia Bighin, Eva Blondeaux, Michelino De Laurentiis, Enrichetta Valle, Francesco Cognetti, Cecilia Nisticò, Sabino De Placido, Ornella Garrone, Teresa Gamucci, Filippo Montemurro, Fabio Puglisi, Barbara Cardinali, Piero Fregatti, Loredana Miglietta, Francesco Boccardo, Marcello CeppiLucia Del Mastro, GIM2 Investigators

Istituto Oncologico Candiolo

Research output: Contribution to journal › Article › peer-review

Abstract

Luminal A-like and luminal B-like subtypes have different sensitivity to (neo)adjuvant chemotherapy, but their role in predicting dose-dense (DD) efficacy in the high-risk setting is unknown. In this exploratory analysis of the Gruppo Italiano Mammella 2 (GIM2) trial, we investigated DD efficacy according to luminal-like subtypes. Patients with node-positive early breast cancer were randomised to receive either DD or standard-interval (SI) anthracycline-based chemotherapy followed by paclitaxel. In our analysis, luminal A-like cohort was identified as having a Ki67

Original language	Undefined/Unknown
Pages (from-to)	43-51
Number of pages	9
Journal	European Journal of Cancer
Volume	136
DOIs	https://doi.org/10.1016/j.ejca.2020.05.007
Publication status	Published - Sep 1 2020

Keywords

Adult
Aged
80 and over
Antineoplastic Combined Chemotherapy Protocols
administration & dosage
adverse effects
pharmacology
Breast Neoplasms
diagnosis
drug therapy
mortality
pathology
Chemotherapy
Adjuvant
Cohort Studies
Disease Progression
Dose-Response Relationship
Drug
Female
Humans
Immunohistochemistry
Middle Aged
Neoplasm Staging
Phenotype
Prognosis
Receptor
ErbB-2
metabolism
Receptors
Estrogen
Progesterone
Survival Analysis
Breast cancer
Dose-dense chemotherapy
Hormone receptor-positive
Luminal subtype

Access to Document

10.1016/j.ejca.2020.05.007

Cite this

Conte, B., Bruzzone, M., Lambertini, M., Poggio, F., Bighin, C., Blondeaux, E., De Laurentiis, M., Valle, E., Cognetti, F., Nisticò, C., De Placido, S., Garrone, O., Gamucci, T., Montemurro, F., Puglisi, F., Cardinali, B., Fregatti, P., Miglietta, L., Boccardo, F., ... Investigators, GIM. (2020). Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial. European Journal of Cancer, 136, 43-51. https://doi.org/10.1016/j.ejca.2020.05.007

Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial. / Conte, Benedetta; Bruzzone, Marco; Lambertini, Matteo; Poggio, Francesca; Bighin, Claudia; Blondeaux, Eva; De Laurentiis, Michelino; Valle, Enrichetta; Cognetti, Francesco; Nisticò, Cecilia; De Placido, Sabino; Garrone, Ornella; Gamucci, Teresa; Montemurro, Filippo; Puglisi, Fabio; Cardinali, Barbara; Fregatti, Piero; Miglietta, Loredana; Boccardo, Francesco; Ceppi, Marcello; Del Mastro, Lucia; Investigators, GIM2.

In: European Journal of Cancer, Vol. 136, 01.09.2020, p. 43-51.

Research output: Contribution to journal › Article › peer-review

Conte, B, Bruzzone, M, Lambertini, M, Poggio, F, Bighin, C, Blondeaux, E, De Laurentiis, M, Valle, E, Cognetti, F, Nisticò, C, De Placido, S, Garrone, O, Gamucci, T, Montemurro, F, Puglisi, F, Cardinali, B, Fregatti, P, Miglietta, L, Boccardo, F, Ceppi, M, Del Mastro, L & Investigators, GIM 2020, 'Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial.', European Journal of Cancer, vol. 136, pp. 43-51. https://doi.org/10.1016/j.ejca.2020.05.007

Conte B, Bruzzone M, Lambertini M, Poggio F, Bighin C, Blondeaux E et al. Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial. European Journal of Cancer. 2020 Sep 1;136:43-51. https://doi.org/10.1016/j.ejca.2020.05.007

Conte, Benedetta ; Bruzzone, Marco ; Lambertini, Matteo ; Poggio, Francesca ; Bighin, Claudia ; Blondeaux, Eva ; De Laurentiis, Michelino ; Valle, Enrichetta ; Cognetti, Francesco ; Nisticò, Cecilia ; De Placido, Sabino ; Garrone, Ornella ; Gamucci, Teresa ; Montemurro, Filippo ; Puglisi, Fabio ; Cardinali, Barbara ; Fregatti, Piero ; Miglietta, Loredana ; Boccardo, Francesco ; Ceppi, Marcello ; Del Mastro, Lucia ; Investigators, GIM2. / Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial. In: European Journal of Cancer. 2020 ; Vol. 136. pp. 43-51.

@article{f673f606ba8f4c569ff0efae06346adb,

title = "Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial.",

abstract = "Luminal A-like and luminal B-like subtypes have different sensitivity to (neo)adjuvant chemotherapy, but their role in predicting dose-dense (DD) efficacy in the high-risk setting is unknown. In this exploratory analysis of the Gruppo Italiano Mammella 2 (GIM2) trial, we investigated DD efficacy according to luminal-like subtypes. Patients with node-positive early breast cancer were randomised to receive either DD or standard-interval (SI) anthracycline-based chemotherapy followed by paclitaxel. In our analysis, luminal A-like cohort was identified as having a Ki67 ",

keywords = "Adult, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, administration & dosage, adverse effects, pharmacology, Breast Neoplasms, diagnosis, drug therapy, mortality, pathology, Chemotherapy, Adjuvant, Cohort Studies, Disease Progression, Dose-Response Relationship, Drug, Female, Humans, Immunohistochemistry, Middle Aged, Neoplasm Staging, Phenotype, Prognosis, Receptor, ErbB-2, metabolism, Receptors, Estrogen, Progesterone, Survival Analysis, Breast cancer, Dose-dense chemotherapy, Hormone receptor-positive, Luminal subtype",

author = "Benedetta Conte and Marco Bruzzone and Matteo Lambertini and Francesca Poggio and Claudia Bighin and Eva Blondeaux and {De Laurentiis}, Michelino and Enrichetta Valle and Francesco Cognetti and Cecilia Nistic{\`o} and {De Placido}, Sabino and Ornella Garrone and Teresa Gamucci and Filippo Montemurro and Fabio Puglisi and Barbara Cardinali and Piero Fregatti and Loredana Miglietta and Francesco Boccardo and Marcello Ceppi and {Del Mastro}, Lucia and GIM2 Investigators",

year = "2020",

month = sep,

day = "1",

doi = "10.1016/j.ejca.2020.05.007",

language = "Non definita",

volume = "136",

pages = "43--51",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Ltd",

}

TY - JOUR

T1 - Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial.

AU - Conte, Benedetta

AU - Bruzzone, Marco

AU - Lambertini, Matteo

AU - Poggio, Francesca

AU - Bighin, Claudia

AU - Blondeaux, Eva

AU - De Laurentiis, Michelino

AU - Valle, Enrichetta

AU - Cognetti, Francesco

AU - Nisticò, Cecilia

AU - De Placido, Sabino

AU - Garrone, Ornella

AU - Gamucci, Teresa

AU - Montemurro, Filippo

AU - Puglisi, Fabio

AU - Cardinali, Barbara

AU - Fregatti, Piero

AU - Miglietta, Loredana

AU - Boccardo, Francesco

AU - Ceppi, Marcello

AU - Del Mastro, Lucia

AU - Investigators, GIM2

PY - 2020/9/1

Y1 - 2020/9/1

N2 - Luminal A-like and luminal B-like subtypes have different sensitivity to (neo)adjuvant chemotherapy, but their role in predicting dose-dense (DD) efficacy in the high-risk setting is unknown. In this exploratory analysis of the Gruppo Italiano Mammella 2 (GIM2) trial, we investigated DD efficacy according to luminal-like subtypes. Patients with node-positive early breast cancer were randomised to receive either DD or standard-interval (SI) anthracycline-based chemotherapy followed by paclitaxel. In our analysis, luminal A-like cohort was identified as having a Ki67

AB - Luminal A-like and luminal B-like subtypes have different sensitivity to (neo)adjuvant chemotherapy, but their role in predicting dose-dense (DD) efficacy in the high-risk setting is unknown. In this exploratory analysis of the Gruppo Italiano Mammella 2 (GIM2) trial, we investigated DD efficacy according to luminal-like subtypes. Patients with node-positive early breast cancer were randomised to receive either DD or standard-interval (SI) anthracycline-based chemotherapy followed by paclitaxel. In our analysis, luminal A-like cohort was identified as having a Ki67

KW - Adult

KW - Aged

KW - 80 and over

KW - Antineoplastic Combined Chemotherapy Protocols

KW - administration & dosage

KW - adverse effects

KW - pharmacology

KW - Breast Neoplasms

KW - diagnosis

KW - drug therapy

KW - mortality

KW - pathology

KW - Chemotherapy

KW - Adjuvant

KW - Cohort Studies

KW - Disease Progression

KW - Dose-Response Relationship

KW - Drug

KW - Female

KW - Humans

KW - Immunohistochemistry

KW - Middle Aged

KW - Neoplasm Staging

KW - Phenotype

KW - Prognosis

KW - Receptor

KW - ErbB-2

KW - metabolism

KW - Receptors

KW - Estrogen

KW - Progesterone

KW - Survival Analysis

KW - Breast cancer

KW - Dose-dense chemotherapy

KW - Hormone receptor-positive

KW - Luminal subtype

U2 - 10.1016/j.ejca.2020.05.007

DO - 10.1016/j.ejca.2020.05.007

M3 - Articolo

VL - 136

SP - 43

EP - 51

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

ER -